Thursday, August 29, 2013
• Orexo AB, of Uppsala, Sweden, said it completed a dose-finding study of OX51, a sublingual formulation comprising alfentanil, in patients undergoing prostate biopsy, with the trial meeting its primary endpoint of analgesic efficacy.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.